Cisplatin-conjugated gold nanoparticles as a theranostic agent for head and neck cancer

Erez Shmuel Davidi, Tamar Dreifuss, Menachem Motiei, Eliezer Shai, Dimitri Bragilovski, Leon Lubimov, Marc Jose Jonathan Kindler, Aron Popovtzer, Jeremy Don, Rachela Popovtzer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: The purpose of this study was to develop a nanoplatform, which simultaneously acts as radiosensitizer, drug carrier, and tumor imaging agent for head and neck cancer. Methods: We synthesized 20 nm gold nanoparticles, coated with glucose and cisplatin (CG-GNPs). Their penetration into tumor cells and their cellular toxicity were evaluated in vitro. In vivo experiments were conducted to evaluate their impact on tumor growth and their imaging capabilities. Results: The CG-GNPs showed efficient penetration into tumor cells and similar cellular toxicity as cisplatin alone. Combined with radiation, CG-GNPs led to greater tumor reduction than that of radiation alone and radiation with free cisplatin. The CG-GNPs also demonstrated efficient tumor imaging capabilities. Conclusion: Our CG-GNPs have a great potential to increase antitumor effect, overcome resistance to chemotherapeutics and radiation, and allow imaging-guided therapy.

Original languageEnglish
Pages (from-to)70-78
Number of pages9
JournalHead and Neck
Issue number1
StatePublished - Jan 2018


  • CT
  • cancer
  • cisplatin
  • gold nanoparticles
  • radiotherapy


Dive into the research topics of 'Cisplatin-conjugated gold nanoparticles as a theranostic agent for head and neck cancer'. Together they form a unique fingerprint.

Cite this